334 related articles for article (PubMed ID: 31437431)
1. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
Liu HJ; Krymskaya VP; Henske EP
Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
[TBL] [Abstract][Full Text] [Related]
2. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis.
Astrinidis A; Khare L; Carsillo T; Smolarek T; Au KS; Northrup H; Henske EP
J Med Genet; 2000 Jan; 37(1):55-7. PubMed ID: 10633137
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2.
Maruyama H; Ohbayashi C; Hino O; Tsutsumi M; Konishi Y
Pathol Int; 2001 Aug; 51(8):585-94. PubMed ID: 11564212
[TBL] [Abstract][Full Text] [Related]
8. [
Verwer EE; Kavanagh TR; Mischler WJ; Feng Y; Takahashi K; Wang S; Shoup TM; Neelamegam R; Yang J; Guehl NJ; Ran C; Massefski W; Cui Y; El-Chemaly S; Sadow PM; Oldham WM; Kijewski MF; El Fakhri G; Normandin MD; Priolo C
Clin Cancer Res; 2018 Dec; 24(23):5925-5938. PubMed ID: 30054282
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis.
Xu KF; Xu W; Liu S; Yu J; Tian X; Yang Y; Wang ST; Zhang W; Feng R; Zhang T
Semin Respir Crit Care Med; 2020 Apr; 41(2):256-268. PubMed ID: 32279296
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex.
Tian X; Glass JE; Kwiatkowski DJ; Towbin AJ; Li Y; Sund KL; Krueger DA; Franz DN; McCormack FX; Gupta N
Ann Am Thorac Soc; 2021 May; 18(5):815-819. PubMed ID: 33171065
[No Abstract] [Full Text] [Related]
11. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.
Carsillo T; Astrinidis A; Henske EP
Proc Natl Acad Sci U S A; 2000 May; 97(11):6085-90. PubMed ID: 10823953
[TBL] [Abstract][Full Text] [Related]
12. Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.
von Ranke FM; Zanetti G; e Silva JL; Araujo Neto CA; Godoy MC; Souza CA; Mançano AD; Souza AS; Escuissato DL; Hochhegger B; Marchiori E
Lung; 2015 Oct; 193(5):619-27. PubMed ID: 26104489
[TBL] [Abstract][Full Text] [Related]
13. Lymphangioleiomyomatosis and tuberous sclerosis complex.
Chorianopoulos D; Stratakos G
Lung; 2008; 186(4):197-207. PubMed ID: 18408969
[TBL] [Abstract][Full Text] [Related]
14. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.
Smolarek TA; Wessner LL; McCormack FX; Mylet JC; Menon AG; Henske EP
Am J Hum Genet; 1998 Apr; 62(4):810-5. PubMed ID: 9529362
[TBL] [Abstract][Full Text] [Related]
15. Lymphangioleiomyomatosis and TSC2-/- cells.
Darling TN; Pacheco-Rodriguez G; Gorio A; Lesma E; Walker C; Moss J
Lymphat Res Biol; 2010 Mar; 8(1):59-69. PubMed ID: 20235888
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of lymphangioleiomyomatosis complicated by renal angiomyolipomas.
Mizushina Y; Bando M; Hosono T; Mato N; Nakaya T; Ishii Y; Yamasawa H; Sugiyama Y
Intern Med; 2011; 50(4):285-9. PubMed ID: 21325759
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
[TBL] [Abstract][Full Text] [Related]
18. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
[TBL] [Abstract][Full Text] [Related]
19. Tuberous sclerosis complex for the pulmonologist.
Rebaine Y; Nasser M; Girerd B; Leroux C; Cottin V
Eur Respir Rev; 2021 Sep; 30(161):. PubMed ID: 34348978
[TBL] [Abstract][Full Text] [Related]
20. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]